secwatch.observer — SEC 8-K summary
======================================

Issuer:     Valion Bio, Inc. (VBIO)
CIK:        0001787740
Form:       8-K
Filed at:   2023-06-16T23:59:59+00:00
Accession:  0000950170-23-028676
Event type: other
Sentiment:  negative
Materiality: 0.70
Item codes: 5.07, 8.01
LLM model:  deepseek-v4-flash:cloud@v2

Tivic Health shareholders reject reverse stock split proposal; Dean Zikria elected director
--------------------------------------------------------------------------------

- Reverse stock split (1:5 to 1:30) failed; 14.0M votes for (47% of outstanding) insufficient to pass.
- Dean Zikria elected as Class II director with 9.2M votes for; no opposing votes recorded.
- Auditor Rosenberg Rich Baker Berman ratified for fiscal year 2023 with 15.5M votes for.
- Non-executive directors each granted options for 25,000 shares at $0.093, vesting over 3 years.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1787740/000095017023028676/0000950170-23-028676-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1787740/000095017023028676/tivc-20230614.htm
  HTML page:      https://secwatch.observer/filing/0000950170-23-028676

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer